Ii-Key definition
Examples of Ii-Key in a sentence
The Licensing shall be effective as of the date of the Ii-Key Innovative Vaccine Development Agreement and is perpetual and will not be revoked or terminated except for the material breach by the Joint Entity.
Party B, owns patents and technologies related to Ii-Key peptide vaccine, and is responsible for providing technology, clinical data, patents and other exclusive rights to the Joint Entity.
Because the Ii-Key is specific for human HLA complexes and HLA varies across ethnic populations, the Ii-Key-SARS-CoV-2 epitope peptides that work in the U.S. population may not be optimal for the East Asian population.
Subject to any reserved rights under this Agreement, Party B hereby grants to the Joint Entity a royalty-bearing, non-transferable, sub licensable license to develop, produce and commercialize the Licensed Technology within the Licensed Territory and the Licensed Area based on Party B's Technology as set forth in Section 1.1 of the the Ii-Key Innovative Vaccine Development Agreement (the "Licensing").
Therefore, following the U.S. blood screening program, analyzing the T-Cell response data, and evaluating the HLA interactions of the Ii-Key-SARS-CoV-2 peptides, the cooperative research team will mutually determine which Ii-Key epitope peptides are optimal for the Chinese population, and conduct additional in-vitro T-Cell assays using convalescent blood samples from patients who have recovered from COVID-19 to develop vaccines to be used in China.
With a multi-country approach, it is the Parties' goals to conduct as many clinical trials as possible to ensure efficacy of the vaccine is generalizable or suited to the native patients and to further obtain commercial license for sale of Ii-Key/ COVID-19 Peptide Vaccine from the Malaysia Ministry of Health.
Human Ii-Key does not bind to animal MHC complexes to activate animal CD-4 responses.
Party A, initiates and organizes all parties work together to establish a joint entity in China, provides other funds and financial guarantee in addition to Party D's contribution, and manages the cooperative research team to quickly develop and transfer Party B's Ii-Key Vaccine technology in China.
The final Ii-Key polypeptide vaccine formulation will be grouped by HLA type.
These facilities will include laboratories for Ii-Key peptide vaccine synthesis, analysis, in vivo testing, and phase I, phase II and phase III clinical research Party B hereby authorizes the Joint Entity to use Party B's Technology as listed in Exhibit B for the research, development and commercialization of products and technology in China according to this Agreement, see Exhibit A for details of the authorization.